Current Symptomatic and Disease-Modifying Treatments in Multiple System Atrophy
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
In: International Journal of Molecular Sciences 21.8 (2020): 2775.
- Ereignis
-
Veröffentlichung
- (wo)
-
Erlangen
- (wer)
-
Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU)
- (wann)
-
2020
- Urheber
-
Mészáros, Lisa
Hoffmann, Alana
Wihan, Jeanette
Winkler, Jürgen
- DOI
-
10.3390/ijms21082775
- URN
-
urn:nbn:de:bvb:29-opus4-204724
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:30 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Mészáros, Lisa
- Hoffmann, Alana
- Wihan, Jeanette
- Winkler, Jürgen
- Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU)
Entstanden
- 2020
Ähnliche Objekte (12)
Expression des CEA im ersten Trimenon der Schwangerschaft
Distinct neuroinflammatory pattern in multiple system atrophy
Generation and characterization of human oligodendroglia as cellular model for Multiple System Atrophy
Glial Dysfunction in Multiple System Atrophy
Compensatory mechanisms and therapeutic approaches in neuronal protein aggregation disorders
Modeling neurodevelopment and cortical dysfunction in SPG11-linked hereditary spastic paraplegia using human induced pluripotent stem cells
Das gastrointestinale Mikrobiom beim idiopathischen Parkinson-Syndrom: Zentrale Rolle von Kovariaten
The autophagy-lysosomal pathway in aggregation, release, and toxicity of alpha-synuclein
Current experimental disease-modifying therapeutics for multiple system atrophy
Combination disease‐modifying treatment in spinal muscular atrophy: a proposed classification
Type-1 spinal muscular atrophy cohort before and after disease-modifying therapies
MAdCAM-1 and alpha-Synuclein as endogenous regulators of immune responses and tissue susceptibility in neuroinflammation
Expression des CEA im ersten Trimenon der Schwangerschaft
Distinct neuroinflammatory pattern in multiple system atrophy
Generation and characterization of human oligodendroglia as cellular model for Multiple System Atrophy
Glial Dysfunction in Multiple System Atrophy
Compensatory mechanisms and therapeutic approaches in neuronal protein aggregation disorders
Modeling neurodevelopment and cortical dysfunction in SPG11-linked hereditary spastic paraplegia using human induced pluripotent stem cells
Das gastrointestinale Mikrobiom beim idiopathischen Parkinson-Syndrom: Zentrale Rolle von Kovariaten
The autophagy-lysosomal pathway in aggregation, release, and toxicity of alpha-synuclein
Current experimental disease-modifying therapeutics for multiple system atrophy
Combination disease‐modifying treatment in spinal muscular atrophy: a proposed classification
Type-1 spinal muscular atrophy cohort before and after disease-modifying therapies
MAdCAM-1 and alpha-Synuclein as endogenous regulators of immune responses and tissue susceptibility in neuroinflammation
Expression des CEA im ersten Trimenon der Schwangerschaft
Distinct neuroinflammatory pattern in multiple system atrophy
Generation and characterization of human oligodendroglia as cellular model for Multiple System Atrophy
Glial Dysfunction in Multiple System Atrophy
Compensatory mechanisms and therapeutic approaches in neuronal protein aggregation disorders
Modeling neurodevelopment and cortical dysfunction in SPG11-linked hereditary spastic paraplegia using human induced pluripotent stem cells
Das gastrointestinale Mikrobiom beim idiopathischen Parkinson-Syndrom: Zentrale Rolle von Kovariaten
The autophagy-lysosomal pathway in aggregation, release, and toxicity of alpha-synuclein
Current experimental disease-modifying therapeutics for multiple system atrophy
Combination disease‐modifying treatment in spinal muscular atrophy: a proposed classification
Type-1 spinal muscular atrophy cohort before and after disease-modifying therapies